<div>
  <ul>
    <li>
      <p>
        Multidisciplinary Association for Psychedelic Studies (MAPS) has rebranded and changed its name to &quot;Lykos Therapeutics.&quot; Further, the company has secured over USD 100 million in its Series A funding round. The funding round was led by Helena, with participation from other investors.
      </p>
    </li>
    <li>
      <p>
        The new funds will be used toward regulatory and pre-launch activities pertaining to its investigational MDMA-assisted therapy targeted at post-traumatic stress disorder (PTSD).&nbsp;
      </p>
    </li>
    <li>
      <p>
        The company has submitted a new drug application to the FDA for its MDMA-assisted therapy, which has completed two Phase III clinical trials for PTSD. If approved, it will be the first-ever psychedelic-assisted therapy intended for PTSD patients.&nbsp;
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://lykospbc.com/press-releases/maps-public-benefit-corporation-announces-oversubscribed-series-a-financing-and-renames-to-lykos-therapeutics/">
      Press release
    </a>
  </p>
</div>


Psychedelic Medicine

INCUMBENTS_PRESENT

<div>
 <p>The Multidisciplinary Association for Psychedelic Studies (MAPS) has changed its name to "Lykos Therapeutics" and raised over USD 100 million in a Series A funding round led by Helena. Other investors also participated in this round.</p>
 <p>The newly secured capital will fund regulatory and pre-launch activities for Lykos Therapeutics’ investigational MDMA-assisted therapy for post-traumatic stress disorder (PTSD).</p>
 <p>A new drug application for the MDMA-assisted therapy, which has undergone two Phase III clinical trials for PTSD, has been submitted to the FDA. If granted approval, this therapy will be the first psychedelic-assisted treatment intended for PTSD patients.</p>
</div>

MAPS renames to Lykos Therapeutics; raises USD 100 million in Series A funding

PROMINENT_CATEGORY

<div>
 <p>The Canadian company Numinus Wellness, which specializes in psychedelic substances, has formed a partnership with a body called the Multidisciplinary Association for Psychedelic Studies (MAPS). Their joint aim is to offer psychedelic experiences to practitioners as part of a clinical study.</p>
 <p>The arrangement is reliant on Health Canada approving Numinus's Clinical Trial Application (CTA). If this happens, Numinus will gain exclusivity over a clinical trial created for practitioners who wish to explore MDMA-assisted therapy. By observing and joining in MDMA sessions, practitioners hope to further their understanding of psychedelic-assisted therapy. </p>
 <p>The MDMA used in this clinical trial will be of clinical-grade and will be manufactured by Optimi. This company, also based in Canada, concentrates on producing and providing psychedelic substances to be utilized in clinical trials. To begin with, the trial will be based at Numinus's Vancouver clinics, but there is the possibility that it may be extended to other sites in the future. </p>
 
</div>

Numinus partners with MAPS to offer psychedelic experiential opportunities for practitioners

<div>
 <p>Awakn Life Sciences, a psychedelics company based in Toronto, has entered into a Memorandum of Understanding (MoU) with the Multidisciplinary Association for Psychedelic Studies (MAPS). MAPS is a non-profit research and education organization located in California. The partnership is set to investigate the use of 3,4-Methylenedioxymethamphetamine (MDMA)-assisted therapy as a possible treatment for alcohol use disorder (AUD). The specific terms and financial aspects of this partnership are yet to be made public.</p>
 <p>Under the agreement, Awakn will have access to the vast research database of MAPS as well as their expertise. This will be beneficial in supporting Awakn's forthcoming Phase 2 and Phase 3 clinical trials on MDMA for the treatment of AUD in Europe. The pair is also considering obtaining an exclusive commercial license, which would allow them to market and commercialize MDMA-assisted therapy for AUD in an ethical manner.</p>
</div>

Awakn Life Sciences to partner with MAPS to explore MDMA therapy

<div>
 <p>Psychedelic life sciences company, Wesana Health, based in Illinois has entered into a Memorandum of Understanding (MOU) with the Multidisciplinary Association for Psychedelic Studies (MAPS). The California-based non-profit research and education organization will collaborate with Wesana on researching psychedelic-assisted therapy for treating traumatic brain injuries (TBI). To initiate this undertaking, Wesana has committed an introductory fee of USD 1.5 million.</p>
 <p>The funds from Wesana will be used in a MAPS subsidiary, called MAPS Public Benefit Corporation (MAPS PBC). The objective is to assemble a team tasked with evaluating the legal, scientific, and operational facets of the forthcoming joint venture. These funds will also serve in expediting MAPS' research on the use of 3,4-Methyl​enedioxy​methamphetamine (MDMA)-assisted therapy for treating traumatic brain injuries.</p>
 <p>In this collaborative research effort, Wesana will be able to leverage MAPS' vast wealth of research expertise and knowledge to develop its drug pipeline further. Additionally, both parties will focus on acquiring an exclusive commercial license to employ MDMA for TBI treatments, assess the possibility of a revenue share agreement, and look into exploring more avenues of research.</p>
</div>

Wesana Health collaborates with MAPS with initial investment of USD 1.5 million

<div>
 <p>The Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit organization from California, has released the results of the first Phase 3 clinical trial from November 2020. This trial studied the efficiency of 3,4-methylenedioxy-N-methylamphetamine (MDMA), a psychedelic compound, in treating post-traumatic stress disorder (PTSD).</p>
 <p>Out of the 90 trial participants who received the MDMA therapy, 67% were no longer diagnosed with PTSD two months later. This is a stark contrast to the 32% recovery rate among participants who only received a placebo. Apart from a few mild symptoms in some participants, there were no significant negative side effects from the MDMA.</p>
 <p>The next step for MAPS towards medical approval for MDMA is to demonstrate effectiveness in a second Phase 3 clinical trial. This trial is currently ongoing with 100 participants and US Food and Drug Administration (FDA) approval hinges on its success. MAPS hopes to receive this approval by 2023.</p>
 
</div>

All Updates

MAPS renames to Lykos Therapeutics; raises USD 100 million in Series A funding

Numinus partners with MAPS to offer psychedelic experiential opportunities for practitioners

Awakn Life Sciences to partner with MAPS to explore MDMA therapy

Wesana Health collaborates with MAPS with initial investment of USD 1.5 million

MDMA therapy on track for FDA approval with promising Phase 3 clinical trial results

Psychedelic Medicine

MAPS renames to Lykos Therapeutics; raises USD 100 million in Series A funding

Contact us